Luye Pharma accorde à Zambon les droits exclusifs de commercialisation en Suisse de son traitement innovant contre la maladie d'Alzheimer, le Patch Transdermique Multi-Jours de Rivastigmine

By In The News
November 11, 2021 in The Headlines

Followers 0

Recommended Posts

In The News

Posted November 11, 2021

- Share

Posted November 11, 2021

BÂLE, Suisse, 11 novembre 2021 /PRNewswire/ -- Le Luye Pharma Group (Luye Pharma) a annoncé aujourd'hui que sa filiale Luye Pharma Switzerland AG a conclu un accord avec Zambon Switzerland (Zambon), en vertu duquel la société accorde à Zambon les droits exclusifs de commercialisation du...

View the full article

Link to comment

Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign in

Already have an account? Sign in here.

Followers 0

Go to topic listing

Most Contributions
1. In The News
  219854
2. Jaydee
  16745
3. Kip Powick
  12211
4. deicer
  12196
5. dagger
  9595
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270.1k
- Total Posts
  
  558.6k

Sign In

Luye Pharma accorde à Zambon les droits exclusifs de commercialisation en Suisse de son traitement innovant contre la maladie d'Alzheimer, le Patch Transdermique Multi-Jours de Rivastigmine

Recommended Posts

In The News

Link to comment

Share on other sites

Create an account or sign in to comment

Create an account

Sign in

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support